fondaparinux 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
synthetic heparinoids	1236	104993-28-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fondaparinux fondaparin heparin pentasaccharide fondaparinux sodium arixtra fondaparin sodium	Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. Molecular weight: 1508.22 Formula: C31H53N3O49S8 CLOGP: -10.96 LIPINSKI: 3 HAC: 52 HDO: 19 TPSA: 805.48 ALOGS: -2.28 ROTB: 27

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fondaparinux
fondaparin
heparin pentasaccharide
fondaparinux sodium
arixtra
fondaparin sodium

Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.

Molecular weight: 1508.22
Formula: C31H53N3O49S8
CLOGP: -10.96
LIPINSKI: 3
HAC: 52
HDO: 19
TPSA: 805.48
ALOGS: -2.28
ROTB: 27

Drug dosage:

Dose	Unit	Route
2.50	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	20 mg/mL	Bocci G, Oprea TI, Benet LZ
t_half (Half-life)	19.30 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	1 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
fu (Fraction unbound in plasma)	0.21 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.14 L/kg	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
CL (Clearance)	0.07 mL/min/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 7 of 7 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 7, 2001	FDA	MYLAN IRELAND LTD

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haematoma	645.69	17.87	233	9896	34587	63444306
Muscle haemorrhage	356.33	17.87	86	10043	3093	63475800
Pulmonary embolism	276.14	17.87	192	9937	116492	63362401
Anaemia	233.12	17.87	259	9870	293171	63185722
Shock haemorrhagic	178.44	17.87	65	10064	9830	63469063
Cerebral haemorrhage	174.25	17.87	89	10040	30640	63448253
Heparin-induced thrombocytopenia	166.36	17.87	51	10078	4531	63474362
Incorrect product administration duration	165.11	17.87	64	10065	11482	63467411
Deep vein thrombosis	142.05	17.87	113	10016	83687	63395206
Haemorrhage	133.81	17.87	96	10033	60926	63417967

Showing 1 to 10 of 92 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haematoma	211.27	18.90	102	6725	25503	34924601
Incorrect product administration duration	194.77	18.90	61	6766	4750	34945354
Muscle haemorrhage	133.35	18.90	43	6784	3675	34946429
Heparin-induced thrombocytopenia	119.83	18.90	44	6783	5551	34944553
Cerebral haemorrhage	100.09	18.90	70	6757	34867	34915237
Pulmonary embolism	99.27	18.90	104	6723	89642	34860462
Anaemia	96.56	18.90	167	6660	233168	34716936
Haemorrhage	94.41	18.90	79	6748	51291	34898813
Shock haemorrhagic	86.83	18.90	43	6784	11311	34938793
Post procedural haemorrhage	68.18	18.90	33	6794	8256	34941848

Showing 1 to 10 of 44 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haematoma	639.40	18.13	260	12773	51935	79679420
Muscle haemorrhage	300.31	18.13	87	12946	6213	79725142
Pulmonary embolism	292.05	18.13	234	12799	171420	79559935
Heparin-induced thrombocytopenia	255.47	18.13	85	12948	9597	79721758
Cerebral haemorrhage	245.13	18.13	139	12894	57534	79673821
Anaemia	230.71	18.13	321	12712	444694	79286661
Incorrect product administration duration	218.73	18.13	80	12953	11942	79719413
Shock haemorrhagic	191.98	18.13	84	12949	19976	79711379
Haemorrhage	162.74	18.13	128	12905	90990	79640365
Deep vein thrombosis	156.39	18.13	141	12892	120778	79610577

Showing 1 to 10 of 99 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	B01AX05	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Other antithrombotic agents
CHEBI has role	CHEBI:50249	anticoagulants
FDA EPC	N0000175637	Factor Xa Inhibitor
FDA MoA	N0000175635	Factor Xa Inhibitors
MeSH PA	D000925	Anticoagulants
MeSH PA	D000991	Antithrombins
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D065427	Factor Xa Inhibitors
MeSH PA	D006401	Hematologic Agents
MeSH PA	D011480	Protease Inhibitors

Showing 1 to 10 of 11 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Deep venous thrombosis	indication	128053003
Pulmonary thromboembolism	indication	233935004
Prevention of deep vein thrombosis	indication	439993001
Myocardial infarction	off-label use	22298006	DOID:5844
Acute coronary syndrome	off-label use	394659003
Diabetic retinopathy	contraindication	4855003	DOID:8947
Gastrointestinal ulcer	contraindication	40845000
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Operation on brain	contraindication	70586009

Showing 1 to 10 of 25 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.23	acidic
pKa10	13.69	acidic
pKa2	0.94	acidic
pKa3	2.46	acidic
pKa4	3.08	acidic
pKa5	11.49	acidic
pKa6	11.98	acidic
pKa7	12.26	acidic
pKa8	12.43	acidic
pKa9	12.91	acidic

Showing 1 to 10 of 10 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Antithrombin-III	Secreted	P01008	ANT3_HUMAN	ACTIVATOR	Kd	7.49		IUPHAR	CHEMBL
Coagulation factor X	Enzyme	P00742	FA10_HUMAN		IC50	7		CHEMBL

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
NTO	PDB_CHEM_ID
009549	NDDF
009550	NDDF
114870-03-0	SECONDARY_CAS_RN
16268	MMSL
184641	MMSL
18938	MMSL
321208	RXNORM
385517000	SNOMEDCT_US
395236007	SNOMEDCT_US

Showing 1 to 10 of 29 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ARIXTRA	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5501	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	NDA	27 sections
ARIXTRA	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5652	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	NDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3443	INJECTION	2.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3454	INJECTION	5 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3465	INJECTION	7.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3476	INJECTION	10 mg	SUBCUTANEOUS	ANDA	27 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-154	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-155	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-156	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-157	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	ANDA	28 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next